Clinical Data GSK hails ‘unprecedented’ cure rates with hep B drug PharmaphorumThe B-Well trials of GSK's bepirovirsen position the antisense drug as a "major step towards a cure for hepatitis B infection," according to experts.Infectious DiseaseRead full story pharminent May 28, 2026 (Last updated: May 28, 2026) Pharmaphorum The B-Well trials of GSK’s bepirovirsen position the antisense drug as a “major step towards a cure for hepatitis B infection,” according to experts. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancerNext: France ‘first EU country to cover obesity drugs’ Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
